NCT01489761

LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

Percutaneous Treatment of Very LONG Native Coronary Lesions With Drug-Eluting Stent-VI: Everolimus-eluting Versus Zotarolimus-Eluting Stents

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 302 (actual)
• Sponsor: Seung-Jung Park · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, study to compare the efficacy of zotarolimus-eluting stent (Resolute Integrity or Resolute Onyx stent) or everolimus-eluting stent (Xience Prime or Xience Xpedition or Xience Alpine stent) for very long coronary lesions.

Detailed description

Following angiography, patients with significant diameter stenosis \> 50% and lesion length (\> 50mm) requiring at least 2 multiple long-stent placement by visual estimation and eligible for LONG-DES VI trial inclusion and exclusion criteria will be randomized 1:1 to zotarolimus-eluting stent (Resolute Integrity or Resolute Onyx stent) or everolimus-eluting stent (Xience Prime or Xience Xpedition or Xience Alpine stent) by the stratified randomization method.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DEVICE	percutaneous coronary intervention	drug eluting stent implantation

Timeline

• Start date: 2012-01-01
• Primary completion: 2017-02-14
• Completion: 2017-02-14
• First posted: 2011-12-12
• Last updated: 2017-02-24

Locations

11 sites across 1 country: South Korea